Imat Imatinib – 100 mg, 400 mg (1 pack / 10 tabs) Tablets

At a Glance

Brand name: Imat

Generic name: Imatinib mesylate

Active ingredient: Imatinib

Strengths & packs: Imat 100 mg (1 pack / 10 tablets); Imat 400 mg (1 pack / 10 tablets)

Dosage form: Oral film-coated tablets

Main indication: Philadelphia chromosome–positive chronic myeloid leukemia (CML) and selected GIST

Therapeutic class: Tyrosine kinase inhibitor (TKI)

Use in therapy: First-line and subsequent targeted therapy for Ph+ CML and indicated solid tumors

Prescription status: Prescription-only anticancer medicine

Supplied by: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from moisture and light

Product Description

Imat 100 mg and Imat 400 mg tablets are
generic imatinib mesylate medicines used as part of targeted therapy for specific blood cancers and solid tumors.
Imatinib is a tyrosine kinase inhibitor (TKI) that has transformed the management of
Philadelphia chromosome–positive chronic myeloid leukemia (CML) and many gastrointestinal stromal tumors (GIST).
This variable product listing combines both strengths so you can buy Imat online in either
100 mg (1 pack / 10 tablets) or 400 mg (1 pack / 10 tablets) according to your specialist’s prescription.

Imat imatinib tablets are commonly prescribed as long-term daily therapy. In chronic phase CML,
imatinib tablets can help control leukemic cell counts, maintain remission and support long-term disease control.
Imat 100 mg tablets are useful when flexible dosing or smaller adjustments are needed, while
Imat 400 mg tablets offer a convenient standard-dose option. Because
Imat is a generic imatinib product, it contains the same active ingredient as branded imatinib but is often available at more accessible USD pricing,
which is important for extended treatment courses.

Each Imat tablet contains imatinib mesylate corresponding to the stated strength of imatinib (100 mg or 400 mg).
The tablets are taken orally with water, usually once daily or split into two doses, depending on the total daily dose and tolerability.
When you order Imat online from Generic Meds Mart, you receive imatinib tablets supplied by licensed manufacturers and authorised distributors
that follow recognised Good Manufacturing Practice standards. Original packaging retains full product details, while outer shipping materials are plain and discreet.

This Imat 100 mg (1 pack / 10 tabs) / 400 mg (1 pack / 10 tabs) product is intended only for patients under the care of a haematologist or oncologist
who has clearly recommended imatinib therapy. Generic Meds Mart does not provide diagnosis or change treatment plans;
this page is designed to support informed discussions with your specialist about access to generic imatinib tablets.

Key Uses

Imat imatinib tablets are generally used for the following indications under specialist supervision:

• Treatment of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic, accelerated or blast phase as directed
• Treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in selected cases
• Treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) expressing KIT (CD117)
• Treatment of other rare malignancies where imatinib is specifically recommended in recognised protocols

Your specialist will determine whether Imat 100 mg or Imat 400 mg is appropriate, how many tablets you should take per day and
how long imatinib therapy should continue.

How Imatinib Works in Chemotherapy

Imatinib is a targeted anticancer agent often grouped within modern systemic chemotherapy and targeted therapy regimens.
Imat contains imatinib, a tyrosine kinase inhibitor (TKI) that blocks abnormal signalling from specific tyrosine kinases such as BCR-ABL in CML
and KIT in many GIST tumours.

Imat imatinib tablets work by binding to these overactive tyrosine kinases and blocking their ATP-binding sites.
This disrupts signalling pathways that drive uncontrolled cancer cell growth and survival. In
chronic myeloid leukemia, this targeted inhibition can reduce leukemic cell counts and support long-term remission.
In GIST, inhibition of KIT can shrink or stabilise tumours that depend on this pathway.

Because imatinib acts as a targeted TKI rather than a traditional cytotoxic drug, its side effect profile differs from standard chemotherapy.
However, Imat is still a potent anticancer medicine and must be monitored carefully by an experienced haematologist or oncologist.

Dosage & Administration

Imat 100 mg and Imat 400 mg imatinib tablets must always be taken exactly as prescribed by your specialist.
Daily dosing, timing and duration of therapy depend on your diagnosis, disease phase, response and tolerance.

• Take Imat tablets by mouth with a large glass of water; some patients are advised to take doses with food to reduce stomach discomfort.
• Swallow the tablets whole. Do not crush, split or chew Imat tablets unless your doctor or pharmacist has given specific instructions.
• The total daily dose may be taken once daily or divided into two doses, depending on your prescription and tolerance.
• Do not change your dose, switch between Imat 100 mg and Imat 400 mg, or stop taking imatinib without clear instructions from your specialist.
• If you miss a dose, follow your doctor’s advice; do not double the next dose to make up for a missed tablet unless your oncologist has recommended it.

Your haematologist or oncologist will schedule regular blood tests and other assessments to monitor your response to
Imat imatinib therapy and adjust doses if needed.

Precautions

Before starting Imat, inform your doctor about your complete medical history and all medicines, supplements or herbal products you use. Important considerations include:

• History of liver disease, kidney impairment or significant cardiac disease
• Pre-existing fluid retention, swelling, heart failure or shortness of breath
• Previous or current gastrointestinal bleeding, ulcers or major stomach or bowel disease
• Use of other anticancer medicines, immunosuppressants or biologic therapies
• Use of strong CYP3A4 inhibitors or inducers, certain antibiotics, antifungals or antiepileptics that may interact with imatinib
• Use of paracetamol, anticoagulants or other medicines that may require careful monitoring with Imat imatinib tablets

Imatinib may not be suitable during pregnancy, and effective contraception is usually recommended during treatment and for a period afterwards, as advised by your doctor.
Breastfeeding is often discouraged while taking Imat. Your specialist will set an appropriate monitoring schedule in your case.

Imatinib Side Effects

Common side effects

Many patients experience side effects when starting Imat imatinib tablets, especially during the first months of treatment. Common reactions may include:

• Nausea, mild vomiting or stomach discomfort
• Diarrhea or, in some cases, constipation
• Fluid retention with swelling of ankles, legs or around the eyes
• Muscle cramps, bone pain or joint discomfort
• Fatigue, weakness or general tiredness
• Mild skin rash or itching

These side effects are often manageable with supportive care or dose adjustments, but you should report persistent or troublesome symptoms to your oncology team.

Serious side effects

Some side effects of imatinib are less common but more serious and require urgent medical attention. Serious reactions may include:

• Marked fluid retention with sudden weight gain, worsening shortness of breath or pronounced leg swelling
• Signs of severe liver problems, such as yellowing of the skin or eyes, dark urine, pale stools or intense upper abdominal pain
• Severe abdominal pain, bloody stools or vomiting blood, which may indicate serious gastrointestinal issues
• Significant changes in blood counts, with fever, frequent infections, unusual bruising or prolonged bleeding
• Severe skin reactions, widespread rash, blistering or involvement of the mouth or eyes

If you experience any of these serious symptoms while taking Imat 100 mg or Imat 400 mg, seek immediate medical care and contact your specialist as soon as possible.

Storage

• Store Imat tablets at room temperature, usually below 25 °C, in a dry place away from direct sunlight and excess heat.
• Keep the tablets in their original blisters and cartons until use to protect them from moisture and light.
• Keep Imat imatinib tablets out of the sight and reach of children and pets.
• Do not use the medicine after the expiry date printed on the packaging.

Ask your pharmacist or follow local regulations for safe disposal of unused or expired imatinib tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on providing reliable access to essential oncology medicines such as
Imat 100 mg and Imat 400 mg imatinib tablets at fair prices in USD.
We work only with licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a documented export track record.

When you buy Imat online from Generic Meds Mart, you benefit from:

• Competitive pricing on generic imatinib tablets compared with many local pharmacies
• Discreet, plain packaging designed to protect your privacy during shipping
• Tracked international delivery options to many destinations
• Clear, structured product information to support discussions with your haematologist or oncologist
• Customer support available to assist with ordering, payment and shipping questions

Our goal is to help you maintain continuity of prescribed targeted therapy with transparent conditions and professional handling of each order.

Order Now

Imat 100 mg and 400 mg imatinib tablets are prescription-only anticancer medicines and must be used strictly under the supervision of a haematologist or oncologist.
Before you order Imat online, ensure that you have a valid prescription or written treatment plan specifying imatinib, the required daily dose and intended duration of therapy.

Select the prescribed strength — Imat 100 mg (1 pack / 10 tablets) or Imat 400 mg (1 pack / 10 tablets) —
choose the appropriate quantity, add Imat to your cart and complete the secure checkout process. Your order will be processed, packed discreetly and shipped with tracking where available.

Generic Meds Mart does not provide diagnosis or personalised medical advice. All treatment decisions, dose changes and monitoring remain the responsibility of your oncology team.

Dasatrue Dasatinib Tablets 50 mg / 70 mg (1 pack / 60 tabs)

At a Glance

Generic Name: Dasatinib

Brand Name: Dasatrue

Strength & Pack Size: 50 mg or 70 mg per tablet; 1 pack / 60 tablets

Dosage Form & Route: Oral tablet, swallowed whole with water

Therapeutic Class: Tyrosine kinase inhibitor (TKI), BCR-ABL inhibitor (targeted anticancer therapy)

Primary Indication: Chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) where dasatinib is appropriate

Typical Use in Therapy: Used within a hematology–oncology plan with response monitoring and blood tests

Prescription Status: Prescription-only medicine

Storage: Store in original packaging as directed; protect from moisture and keep out of reach of children

Product Description

Dasatrue contains dasatinib, a targeted oral tyrosine kinase inhibitor used in CML and Ph+ ALL when a qualified hematology–oncology specialist determines it is appropriate. Dasatrue is supplied as dasatinib tablets in two strengths (50 mg and 70 mg), with this listing covering 1 pack / 60 tablets per selected strength. If you plan to buy Dasatrue online, match the strength to your prescription and monitoring plan rather than choosing based only on price or availability.

In Philadelphia chromosome–positive leukemias, the abnormal BCR-ABL signal is a key driver of malignant cell growth. Dasatinib targets this pathway as a second-generation TKI, and treatment decisions are individualized based on disease phase, prior therapies, response goals, tolerability, and interaction risks. Patients are usually followed with scheduled blood counts and response assessments, and dose changes are made only by the treating team. Dasatrue is prescription-only and should not be started, stopped, or adjusted without specialist supervision.

Generic Meds Mart supplies Dasatrue dasatinib tablets in original manufacturer packaging sourced through licensed channels. Packs typically show the product name, selected strength, active ingredient, batch number, and expiry date to support pharmacy verification on receipt. Orders are shipped in discreet outer packaging, and delivery wording is kept practical (global delivery / international delivery / worldwide delivery) so patients and clinics can coordinate refills with planned monitoring.

Key Uses

Dasatrue (dasatinib) is used for CML and Ph+ ALL when BCR-ABL tyrosine kinase inhibition is clinically appropriate. These conditions require specialist-led monitoring because both efficacy and safety depend on individualized dosing, response checks, and early recognition of complications such as cytopenias or fluid-related effects. Your hematology team defines the treatment goals, what response milestones are expected, and what follow-up schedule is required.

Common Searches and Treatment Contexts for Dasatinib

• Generic Sprycel (Dasatinib): Dasatrue is a therapeutically equivalent generic version of the brand-name drug Sprycel, containing the same active ingredient (dasatinib 50 mg or dasatinib 70 mg) for the treatment of CML and Ph+ ALL.
• BCR-ABL TKI for CML: Dasatinib is a potent second-generation tyrosine kinase inhibitor that targets the BCR-ABL protein, a key driver in Philadelphia chromosome–positive leukemias.
• Dasatinib 50 mg Tablets / Dasatinib 70 mg Tablets: These strengths are used within individualized regimens prescribed by a hematology specialist based on response and tolerability.
• Buy Dasatinib Online: Patients with a confirmed prescription and monitoring plan may seek reliable access to original-packaging dasatinib to maintain therapy continuity.

How Dasatinib Works in Chemotherapy

Dasatinib inhibits tyrosine kinases involved in leukemia cell signaling, including BCR-ABL. In Ph+ disease, BCR-ABL signaling promotes uncontrolled growth and survival of malignant cells. By blocking these signals, dasatinib reduces downstream pathways that cancer cells rely on, supporting disease control when taken consistently as prescribed within a specialist-managed plan.

Because dasatinib is targeted therapy rather than classic cytotoxic chemotherapy, the side-effect profile differs, but monitoring remains essential. Your specialist may monitor blood counts, infection signs, bleeding risk, and symptoms suggestive of fluid accumulation. Treatment decisions should always be made with your hematology team, especially if you take other medicines that may interact.

Dosage & Administration

Dasatrue tablets must be taken exactly as prescribed by your hematology–oncology specialist. Dasatinib dosage is individualized and may be adjusted based on disease phase, treatment response, tolerability, and interacting medicines. Swallow tablets whole with water and follow the schedule provided by your clinic. If you miss a dose, follow your clinic’s instructions rather than taking extra tablets to compensate.

Interactions can be clinically important with dasatinib. Always share a complete list of prescription medicines, over-the-counter products, and supplements with your specialist and pharmacist before starting therapy and before adding anything new. Never stop or change dosing without medical advice, because continuity and monitoring are core parts of safe targeted treatment.

Precautions

Dasatinib can affect blood counts, increasing infection and bleeding risk. Seek medical advice urgently for fever, chills, unusual bruising, prolonged bleeding, black stools, or severe fatigue. Fluid-related effects such as pleural effusion may occur in some patients and can present as cough, chest discomfort, or shortness of breath; new or worsening breathing symptoms should be assessed promptly.

Your specialist will also consider other risk factors and may recommend specific monitoring based on your situation. Pregnancy should be avoided during anticancer therapy, and contraception planning should be discussed with a qualified healthcare professional.

Dasatinib Side Effects

Common side effects

Common dasatinib side effects may include diarrhea, nausea, fatigue, headache, muscle or joint aches, mild rash, and laboratory changes in blood counts. Many effects can be managed within a specialist-led plan, but persistent or worsening symptoms should be discussed with your care team rather than managed by changing the dose independently.

Serious side effects

Serious side effects require urgent medical attention and may include major bleeding, severe or recurrent infections, significant reductions in blood counts, or clinically important fluid accumulation around the lungs. If you develop high fever, heavy bleeding, black stools, chest pain, fainting, or rapidly worsening shortness of breath, seek urgent care and tell clinicians you are taking dasatinib.

Storage

Store Dasatrue in the original packaging as directed on the label, protect from moisture and excessive heat, and keep out of reach of children. Do not use after the expiry date on the carton or blister/bottle. Follow any clinic-specific handling instructions provided for oncology medicines.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for specialty medicines such as Dasatrue dasatinib tablets. Products are supplied in original packaging from licensed channels with batch and expiry information for verification. Pricing is displayed in USD, checkout is secure, and shipments are packed in discreet outer cartons to protect privacy.

For patients managing CML or Ph+ ALL within a monitoring plan, reliable access can support therapy continuity. Global delivery options and tracking can help align refills with blood tests and specialist visits. Generic Meds Mart does not replace your treating doctor, and all clinical decisions about dasatinib therapy, including monitoring and side-effect management, must be made by qualified healthcare professionals.

Order Now

Before you order Dasatrue, you should have a confirmed diagnosis of CML or Ph+ ALL and a treatment plan agreed with your hematology–oncology specialist. Your care team will explain which monitoring tests are required and how often, and they will review interaction risks with your current medicines. Once your plan is confirmed, select the correct strength (Dasatrue 50 mg or Dasatrue 70 mg), add 1 pack / 60 tablets to your cart, and complete checkout in USD.

Do not start therapy on your own, and do not stop or change dosing without medical guidance. If you develop concerning symptoms such as heavy bleeding, high fever, chest pain, or worsening shortness of breath, seek urgent medical care and inform clinicians that you are taking dasatinib.

FAQ about Dasatrue (Dasatinib)

Q1: What is Dasatrue used for?
Dasatrue contains dasatinib, a targeted tyrosine kinase inhibitor used in CML and Ph+ ALL when prescribed by a hematology–oncology specialist as part of a complete treatment plan.

Q2: Is Dasatrue a chemotherapy medicine or targeted therapy?
Dasatrue (dasatinib) is targeted therapy that inhibits BCR-ABL and related kinases in Philadelphia chromosome–positive disease. It still requires specialist supervision and monitoring.

Q3: How should I take Dasatrue tablets?
Take Dasatrue exactly as prescribed. Swallow tablets whole with water and follow your specialist’s schedule and monitoring instructions.

Q4: What should I know about dasatinib dosage and missed doses?
Dasatinib dosage is individualized by your specialist. If you miss a dose, follow your clinic’s instructions and do not take extra tablets unless your specialist tells you to.

Q5: What are common dasatinib side effects to monitor?
Common dasatinib side effects can include diarrhea, fatigue, rash, and changes in blood counts. Report persistent or severe symptoms so your care team can advise safely.

Q6: Is Dasatrue 50 mg or 70 mg the same as Sprycel (Generic Sprycel)?
Dasatrue is Generic Sprycel — it contains the same active ingredient (dasatinib) as Sprycel. It’s used for the same indication at the same strength, while differences may be in manufacturer, inactive ingredients (excipients), tablet appearance, and packaging. If you’re switching between products, confirm the substitution with a qualified healthcare professional.

Zavedos Idarubicin – 5 mg Injection Vial

At a Glance

Generic Name: Idarubicin Hydrochloride

Brand Name: Zavedos 5 mg

Strength & Pack Size: 5 mg idarubicin per vial, 1 single-use vial

Dosage Form & Route: Lyophilised powder for solution for IV injection or infusion

Therapeutic Class: Anthracycline cytotoxic chemotherapy

Primary Indications: Induction and consolidation regimens for acute myeloid leukaemia (AML) and selected acute leukaemia protocols, according to local label

Typical Use in Therapy: Combined with other cytotoxics (such as cytarabine) in intensive hospital-based regimens under haematology supervision

Mode of Action: Intercalates DNA, inhibits topoisomerase II and generates free radicals, disrupting DNA replication and repair

Key Benefits: Established anthracycline backbone in many AML protocols when used with appropriate supportive care

Precautions: Risk of myelosuppression, cardiotoxicity, mucositis and organ toxicity; requires close monitoring in a specialist centre

Storage: Store as directed on the carton, usually below 25 °C, protected from light in the original outer pack

Product Description

Zavedos 5 mg contains idarubicin hydrochloride, an anthracycline cytotoxic medicine used predominantly in the treatment of acute myeloid leukaemia (AML) and selected acute leukaemia protocols. Each single-use vial provides 5 mg of idarubicin as a lyophilised powder that must be reconstituted with a suitable diluent before intravenous administration. Zavedos 5 mg idarubicin injection is restricted to hospital and specialist haematology settings, where experienced teams manage complex induction and consolidation chemotherapy with full access to supportive care.

In many treatment protocols, Zavedos 5 mg idarubicin injection is combined with cytarabine and other agents to achieve remission in AML. It may also appear in variations of acute leukaemia regimens depending on national guidelines, trial data and institutional practice. Because idarubicin is a potent anthracycline with the potential for both short-term and long-term toxicity, its use is carefully weighed against disease severity, patient fitness, prior anthracycline exposure and cardiac status. This is not a medicine for outpatient self-administration; every step from reconstitution to infusion is handled by trained oncology or haematology staff.

Generic Meds Mart supplies Zavedos 5 mg idarubicin injection only in original manufacturer packaging obtained from licensed distributors. Each vial is sealed and carries a clearly printed batch number and expiry date so hospital pharmacies can document traceability. Outer shipping cartons are neutral, without visible references to leukaemia, anthracyclines or idarubicin, helping protect privacy during international delivery. Pricing is shown in USD to support planning for multi-cycle chemotherapy that may involve several vials across induction and consolidation phases.

Key Uses

In clinical practice, Zavedos 5 mg idarubicin injection is used as part of combination chemotherapy for acute myeloid leukaemia and, in some settings, other acute leukaemias where idarubicin is incorporated into validated protocols. Typical uses include induction regimens aimed at achieving complete remission and consolidation courses designed to deepen and maintain the response.

The exact protocol, number of cycles and combination partners differ by region and institutional guidelines. Some centres reserve idarubicin for particular risk groups or disease subtypes, while others use it within standard AML induction regimens. Decisions about whether to use idarubicin rather than other anthracyclines such as daunorubicin are made by haematologists based on evidence, local practice, patient comorbidities and cumulative anthracycline exposure. Zavedos 5 mg is one component of a broader plan that may include further chemotherapy, stem cell transplantation or maintenance strategies.

How Idarubicin Works in Chemotherapy

Idarubicin, the active ingredient in Zavedos 5 mg injection, is an anthracycline antineoplastic agent. It exerts its cytotoxic effect through multiple mechanisms, including DNA intercalation, inhibition of topoisomerase II and generation of free radicals that damage cellular components. By intercalating between DNA base pairs, idarubicin disrupts DNA structure and interferes with replication and transcription. Topoisomerase II inhibition prevents the proper unwinding and re-ligation of DNA strands, further impairing replication and repair.

These actions are particularly harmful to rapidly dividing cells, such as leukaemic blasts in the bone marrow. When Zavedos 5 mg idarubicin injection is combined with other agents like cytarabine, the effects on DNA synthesis and repair can be synergistic, enhancing the likelihood of inducing remission. However, this same potency underlies the risk of damage to normal rapidly dividing cells, including bone marrow progenitors, gastrointestinal mucosa and hair follicles, as well as potential cumulative injury to cardiac tissue over time.

Dosage & Administration

Zavedos 5 mg idarubicin injection must only be prescribed and administered by haematologists or oncologists experienced in intensive leukaemia chemotherapy. Each vial contains 5 mg of idarubicin powder for reconstitution. The dose is typically calculated on the basis of body surface area (mg/m²) and administered intravenously over a defined time interval, often on specific days of a chemotherapy cycle alongside other agents.

Reconstitution and dilution are performed under aseptic, cytotoxic handling conditions in a pharmacy or chemotherapy preparation unit. Nurses trained in cytotoxic administration then deliver the dose via a central or peripheral venous line, monitoring for extravasation and infusion reactions. Zavedos 5 mg idarubicin injection is never given by the patient at home and must not be administered intramuscularly or subcutaneously. Frequent blood counts, biochemistry tests and clinical assessments guide decisions about subsequent doses, cycle timing and supportive interventions such as transfusions or growth factor support.

Precautions

Before initiating Zavedos 5 mg idarubicin injection, the treatment team reviews cardiac function, prior anthracycline exposure, liver and kidney function, performance status and infection risk. Anthracyclines are associated with dose-dependent cardiomyopathy, so baseline assessment of left ventricular ejection fraction is standard, with follow-up imaging where indicated. Patients with significant pre-existing cardiac disease may require alternative regimens or careful modification of anthracycline dosing.

Myelosuppression is expected and often profound, so patients receiving Zavedos 5 mg must be treated in centres capable of delivering transfusions, broad-spectrum antibiotics, antifungals, growth factors and intensive supportive care. Adequate liver and kidney function are important to handle metabolism and excretion of idarubicin and its metabolites. Fertility counselling is usually offered before treatment starts, and effective contraception is advised during therapy and for a period afterwards, as idarubicin is contraindicated in pregnancy and may harm an unborn child.

Idarubicin Side Effects

Common side effects

Common idarubicin side effects in patients receiving Zavedos 5 mg injection include myelosuppression with neutropenia, thrombocytopenia and anaemia; increased susceptibility to infections; hair loss; nausea and vomiting; mucositis affecting the mouth and gastrointestinal tract; diarrhoea or constipation; fatigue; and temporary changes in liver function tests. The urine or tears may take on a reddish colour for a short period due to the anthracycline pigment, which is usually benign but can be alarming if not anticipated.

With experienced supportive care, many of these common idarubicin side effects can be managed. Centres that use Zavedos 5 mg routinely will provide antiemetic regimens, oral care protocols, nutritional support and transfusion strategies. Patients and families are counselled on signs of infection, bleeding and dehydration so they can seek help promptly.

Serious side effects

Serious idarubicin adverse effects require immediate medical attention. These may include severe or prolonged bone marrow suppression leading to septic shock or major haemorrhage; clinically significant cardiotoxicity with heart failure symptoms; severe mucositis preventing oral intake; acute liver or kidney injury; and severe extravasation injury if the drug leaks from the vein into surrounding tissue. Anthracyclines have also been associated with secondary malignancies after long-term follow-up in some patients, though this risk must be weighed against the immediate need to treat life-threatening leukaemia.

Patients are instructed to contact the treatment centre or emergency services urgently if they develop high fever, chills, shortness of breath, chest pain, sudden weight gain with swelling, uncontrolled bleeding, severe mouth or throat pain, confusion, markedly reduced urine output or any other alarming symptom during or after a cycle containing Zavedos 5 mg idarubicin injection. The team may need to adjust further therapy, intensify supportive care or consider alternative regimens.

Storage

Zavedos 5 mg idarubicin injection vials should be stored exactly as described on the product carton and in the package leaflet, usually below 25 °C, protected from light in the original outer carton. Vials must be kept out of the sight and reach of children. Reconstituted solutions have a limited stability window and must be used or discarded according to cytotoxic preparation guidelines. Unused solution, vials, syringes and infusion lines that have come into contact with idarubicin should be disposed of as cytotoxic waste, following local regulations and institutional policies.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to key oncology medicines such as Zavedos 5 mg idarubicin injection. We partner only with licensed manufacturers and authorised distributors that comply with Good Manufacturing Practice and maintain full batch traceability. Each vial of Zavedos 5 mg supplied by Generic Meds Mart is delivered in sealed original packaging so hospital pharmacies can confirm brand, strength, batch number and expiry before release to the chemotherapy unit.

By listing Zavedos 5 mg in USD, we help treatment centres and patients plan for the cost of multi-cycle AML regimens that may require multiple vials. Neutral outer cartons protect confidentiality during international shipping, while tracking (where available) supports coordination between delivery and scheduled chemotherapy cycles. Our role is limited to supply and logistics; all decisions about when and how to use idarubicin remain strictly with the treating haematology or oncology team.

Order Now

Zavedos 5 mg idarubicin injection is a potent anthracycline cytotoxic medicine reserved for specialist use in acute leukaemia chemotherapy. It must never be ordered for unsupervised or home administration. Before arranging supply through Generic Meds Mart, the treating team should confirm the indication, planned protocol, number of cycles, required idarubicin dose per cycle, cumulative anthracycline limits and supportive care resources.

Once that plan is documented, a designated purchaser or pharmacist can calculate the number of Zavedos 5 mg vials needed for the initial induction and consolidation phases. They can then select the appropriate quantity on Generic Meds Mart, add it to the cart and complete secure checkout in USD. Vials will be shipped in discreet outer packaging with full original labelling inside. Patients and caregivers should direct all clinical questions about idarubicin, side effects or dose modifications to their haematology team and must not attempt to handle or administer Zavedos 5 mg themselves.

FAQ about Zavedos (Idarubicin)

Q1: What is Zavedos 5 mg used for?
Zavedos 5 mg contains idarubicin, an anthracycline cytotoxic agent used primarily in induction and consolidation protocols for acute myeloid leukaemia (AML) and selected acute leukaemia regimens, according to local product information and specialist guidelines.

Q2: Can Zavedos 5 mg be given outside hospital?
No. Zavedos 5 mg idarubicin injection is prepared and administered only in hospital or specialist centres with facilities for intensive chemotherapy, cytotoxic handling and full supportive care. It is not suitable for outpatient self-administration.

Q3: How is Zavedos 5 mg administered?
Each vial of Zavedos 5 mg idarubicin injection is reconstituted and further diluted as required, then given intravenously by trained staff. Doses are calculated in mg/m² as part of a larger chemotherapy regimen. Administration routes, infusion times and schedules must follow the official product information and institutional protocols.

Q4: Why is heart monitoring important with idarubicin?
Idarubicin, like other anthracyclines, can cause cumulative cardiotoxicity and may lead to reduced heart function or heart failure. Baseline and follow-up heart assessments, such as echocardiograms, help specialists track cardiac function and adjust anthracycline exposure to reduce risk while still treating the leukaemia effectively.

Q5: What should patients watch for during treatment with Zavedos 5 mg?
Patients and caregivers should pay close attention to fever, chills, signs of infection, unusual bleeding or bruising, severe mouth sores, persistent vomiting or diarrhoea, chest pain, shortness of breath, sudden swelling, profound fatigue or reduced urine output. Any such symptoms should prompt immediate contact with the treatment centre or emergency services, as they may indicate serious idarubicin-related complications.

Xpreza Azacitidine – 100 mg Injection

At a Glance

Generic Name: Azacitidine

Brand Name: Xpreza 100 mg

Strength & Pack Size: 100 mg azacitidine per vial, 1 single-use vial

Dosage Form & Route: Lyophilised powder for subcutaneous injection or intravenous use after reconstitution

Therapeutic Class: Hypomethylating antineoplastic agent (pyrimidine nucleoside analogue)

Primary Indications: Selected myelodysplastic syndromes (MDS), certain AML and chronic myelomonocytic leukaemia (CMML), according to local label

Typical Use in Therapy: Cyclical treatment in specialist haematology units, often as lower-intensity therapy in higher-risk MDS and older AML patients

Mode of Action: Incorporates into RNA/DNA and inhibits DNA methyltransferase, leading to hypomethylation and cytotoxicity in abnormal haematopoietic cells

Key Benefits: Can improve blood counts, delay progression to AML and extend survival in carefully selected patients

Precautions: Requires close monitoring of blood counts, organ function, injection site reactions and infection risk

Storage: Store the vial as per carton instructions, usually refrigerated or below a defined temperature, protected from light until reconstitution

Product Description

Xpreza 100 mg contains azacitidine, a hypomethylating antineoplastic agent used in the treatment of certain myelodysplastic syndromes, selected cases of acute myeloid leukaemia and chronic myelomonocytic leukaemia. Each vial provides 100 mg of azacitidine as a lyophilised powder that must be reconstituted with an appropriate diluent before administration. Xpreza 100 mg azacitidine injection is given in cycles, usually as subcutaneous injections or intravenous infusions in a specialist haematology setting.

For many higher-risk MDS patients and some older adults with AML or CMML, azacitidine offers an important treatment option when intensive induction chemotherapy or transplantation is not appropriate or is being deferred. By targeting abnormal marrow cells and altering gene expression patterns, Xpreza 100 mg azacitidine injection can stabilise disease, improve blood counts, reduce transfusion dependence and delay progression to more aggressive leukaemia in a subset of patients. Treatment is typically long-term and requires patience, as responses may take several cycles to become apparent.

Generic Meds Mart supplies Xpreza 100 mg azacitidine injection in original, sealed oncology packaging from licensed manufacturers and authorised distributors. Vials are shipped in neutral outer cartons that do not mention MDS, AML or azacitidine on the exterior, helping protect patient privacy. Inner packaging retains full information, including brand name, strength, batch number and expiry date, so hospital pharmacies can verify the product before preparing each dose. Pricing is presented in USD, supporting transparent planning for repeated azacitidine cycles that may span many months.

Key Uses

Within the framework of local regulatory approvals and guidelines, Xpreza 100 mg azacitidine injection is used for selected myelodysplastic syndromes, including higher-risk subtypes, and for certain presentations of AML and CMML in adults. Typical candidates include patients with significant cytopenias or higher-risk disease features who may not be suitable for intensive induction chemotherapy. Azacitidine treatment is usually delivered as a 7-day or modified 5–7-day cycle repeated every 28 days, although exact schedules vary by protocol and patient tolerance.

The haematology team will decide whether Xpreza 100 mg azacitidine injection is appropriate based on bone marrow findings, cytogenetics, molecular markers, performance status, comorbidities and patient preferences. Azacitidine may be used as a stand-alone disease-modifying therapy, as a bridge to transplant in selected cases or as a long-term management strategy aimed at improving quality of life and delaying disease progression. It is not a “quick fix” and requires regular clinic visits, laboratory monitoring and supportive care.

How Azacitidine Works in Chemotherapy

Azacitidine, the active ingredient in Xpreza 100 mg injection, is a pyrimidine nucleoside analogue with both hypomethylating and cytotoxic properties. Inside cells, azacitidine is incorporated into RNA and, after conversion to its deoxy form, into DNA. When incorporated into DNA, azacitidine inhibits DNA methyltransferase, an enzyme involved in maintaining normal DNA methylation patterns.

By inhibiting DNA methyltransferase, azacitidine leads to hypomethylation of DNA in rapidly dividing abnormal haematopoietic cells. This can reactivate silenced tumour suppressor genes and alter gene expression profiles in a way that reduces the growth advantage of dysplastic or leukaemic cells. At higher doses, azacitidine also has direct cytotoxic effects, causing damage to abnormal cells that are synthesising DNA.

Through these mechanisms, Xpreza 100 mg azacitidine injection can reduce the burden of abnormal clones in the bone marrow and allow healthier progenitor cells to recover. This may translate into improved blood counts, reduced transfusion needs and delayed transformation to overt leukaemia in some patients. However, the same actions also affect normal dividing cells, which is why careful dose selection and monitoring are essential.

Dosage & Administration

Xpreza 100 mg azacitidine injection must only be prescribed and supervised by haematologists experienced in treating MDS, AML and related disorders. The dose is usually calculated based on body surface area (mg/m²) and adjusted according to response, blood counts and tolerability. After reconstitution, azacitidine can be administered subcutaneously into the abdomen, thigh or upper arm, or given intravenously as an infusion, following the product information and local protocols.

Treatment is typically cyclical, with azacitidine given for several consecutive days followed by a rest period. Patients often receive premedication or supportive antiemetics to reduce nausea and vomiting. Blood counts and biochemistry are checked regularly to guide dose delays or reductions and to decide whether growth factors, transfusions or infection prophylaxis are needed. Xpreza 100 mg azacitidine injection should never be self-prepared or self-administered; all handling and administration are undertaken by trained staff in a clinic or hospital.

Precautions

Before starting Xpreza 100 mg azacitidine injection, the haematology team conducts a thorough review of bone marrow status, blood counts, liver and kidney function, infection history and concomitant medicines. Because azacitidine can cause myelosuppression, patients require ongoing monitoring for neutropenia, thrombocytopenia and anaemia, with timely intervention if counts fall.

Injection site reactions are common with subcutaneous dosing, so patients are advised about rotating injection sites and reporting severe redness, pain or nodules. Nausea, vomiting and diarrhoea are frequent early in treatment, making antiemetics and hydration protocols important. Azacitidine is contraindicated in pregnancy and breastfeeding, and effective contraception is usually recommended during treatment and for a period afterwards. Decisions about continuing, interrupting or stopping Xpreza 100 mg azacitidine injection depend on response, tolerance and evolving clinical status.

Azacitidine Side Effects

Common side effects

Common azacitidine side effects with Xpreza 100 mg injection include low blood counts (neutropenia, thrombocytopenia and anaemia), injection site redness or bruising, nausea, vomiting, diarrhoea or constipation, loss of appetite, fatigue, mild fever, and general weakness. Some patients experience transient kidney or liver test abnormalities, mild headache or injection site pain. These effects are often most noticeable during early cycles and may stabilise or become more manageable as the team refines dosing and supportive care.

Many of these common azacitidine side effects can be addressed with antiemetics, careful hydration, local skin care, growth factor support, transfusions and temporary dose adjustments or delays. Patients are encouraged to keep a symptom diary and bring concerns to clinic visits so that the haematology team can optimise supportive measures.

Serious side effects

Serious azacitidine adverse effects require prompt medical attention. These can include severe or prolonged neutropenia with high risk of infection, sepsis, severe thrombocytopenia with active bleeding, severe gastrointestinal toxicity with dehydration, acute kidney or liver dysfunction, hypersensitivity reactions and, rarely, serious local reactions or tissue damage at injection sites.

Patients should be instructed to contact their treatment centre or emergency services immediately if they develop high fever, chills, shortness of breath, chest pain, uncontrolled vomiting or diarrhoea, black or bloody stools, unusual bleeding or bruising, marked decrease in urine output, confusion or any other alarming symptom. The medical team may need to hold further doses of Xpreza 100 mg azacitidine injection, adjust the regimen or intensify supportive care depending on the severity and suspected cause.

Storage

Xpreza 100 mg azacitidine injection vials should be stored as indicated on the product carton and in the package leaflet, which may include refrigerated storage or a controlled room temperature range. Vials must be kept in the original outer carton to protect from light and should remain out of the reach of children. Reconstituted suspensions or solutions have limited stability and must be prepared and used within the timeframes specified by the manufacturer and local cytotoxic preparation guidelines. Any unused product and materials that have been in contact with azacitidine must be discarded as cytotoxic waste.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on structured access to essential haematology and oncology medicines such as Xpreza 100 mg azacitidine injection. We source only from licensed manufacturers and authorised distributors that comply with Good Manufacturing Practice and provide full batch traceability. Each vial of Xpreza 100 mg is supplied in sealed original packaging, allowing hospital pharmacies and clinic staff to verify brand, strength, batch number and expiry before preparation.

By listing Xpreza 100 mg azacitidine injection in USD, Generic Meds Mart helps patients and centres plan the cost of repeated treatment cycles. Neutral shipping cartons preserve confidentiality during international delivery, while tracking (where available) allows coordination of shipments with clinic appointments and laboratory monitoring. Our role is to support access and logistics; all decisions about whether, when and how to use azacitidine remain entirely with the treating haematology team.

Order Now

Xpreza 100 mg azacitidine injection is a specialised medicine for MDS, AML and CMML that must never be used without a clear plan from an experienced haematologist. Before arranging supply through Generic Meds Mart, the team should confirm diagnosis, risk category, treatment goals, suitability for azacitidine, proposed dosing schedule and expected duration of therapy. They should also ensure that appropriate monitoring, transfusion support and emergency care pathways are in place.

Once this framework is agreed, the centre or designated purchaser can estimate how many vials of Xpreza 100 mg are needed for the first several cycles. They can then select the corresponding quantity on Generic Meds Mart, add it to the cart and complete secure checkout in USD. Medicines are dispatched in discreet outer packaging with full original labelling inside. Patients and caregivers should never attempt to reconstitute or inject azacitidine themselves unless explicitly trained and authorised by their team, and any new or severe symptoms should be reported promptly for evaluation.

FAQ about Xpreza (Azacitidine)

Q1: What is Xpreza 100 mg used for?
Xpreza 100 mg contains azacitidine, a hypomethylating antineoplastic agent used under haematology supervision in selected myelodysplastic syndromes, certain cases of acute myeloid leukaemia and chronic myelomonocytic leukaemia, according to local product information and guidelines.

Q2: Is Xpreza 100 mg given as an injection or a tablet?
Xpreza 100 mg is supplied as a vial of lyophilised powder that is reconstituted and given as a subcutaneous injection or intravenous dose, depending on protocol. It is not an oral tablet and should only be administered by trained healthcare professionals following the official instructions.

Q3: How long will I need to stay on azacitidine?
Many patients receive Xpreza 100 mg azacitidine injection for multiple cycles, often at least six or more, before treatment is fully evaluated. If there is clinical benefit and side effects remain manageable, therapy may continue for an extended period. The haematology team will review response, blood counts and quality of life regularly to decide how long to maintain azacitidine.

Q4: Can Xpreza 100 mg cure my MDS or AML?
Azacitidine is generally considered a disease-modifying treatment rather than a direct cure for most patients. It can improve blood counts, reduce transfusion needs, delay progression and extend survival in selected cases. In some patients it may be used as a bridge to transplantation, which offers the potential for long-term remission. Your team will explain realistic goals for your individual situation.

Q5: What monitoring is needed during treatment with Xpreza 100 mg?
Patients on Xpreza 100 mg azacitidine injection need regular full blood counts, kidney and liver function tests, clinical assessments for infection and bleeding, and review of injection sites and gastrointestinal symptoms. These checks help the team adjust doses, time cycles appropriately and provide supportive care to manage side effects safely.

Spnib 100 mg Dasatinib Tablets (1 bottle / 30 tabs)

At a Glance

Generic Name: Dasatinib

Brand Name: Spnib 100 mg

Strength & Pack Size: 100 mg tablets, 1 bottle / 30 tablets

Dosage Form & Route: Oral film-coated tablets for swallowing whole with water

Therapeutic Class: Second-generation BCR-ABL tyrosine kinase inhibitor and SRC family kinase inhibitor

Primary Indications: Philadelphia chromosome–positive chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL), according to local label

Typical Use in Therapy: Used as first- or subsequent-line TKI option in Ph+ CML or Ph+ ALL under specialist protocols

Mode of Action: Inhibits BCR-ABL and other kinases to block abnormal signalling and leukemic cell proliferation

Key Benefits: Active in many patients resistant or intolerant to imatinib, with rapid and deep molecular responses in appropriately selected cases

Precautions: Myelosuppression, bleeding, fluid retention, pulmonary arterial hypertension and QT prolongation require close monitoring

Storage: Store below 25 °C in the original container, tightly closed and protected from moisture

Product Description

Spnib 100 mg contains dasatinib, an oral second-generation tyrosine kinase inhibitor used in the treatment of Philadelphia chromosome–positive leukemias. It is typically prescribed for Ph+ chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) in adults when a potent BCR-ABL inhibitor is needed, including situations where imatinib has failed due to resistance or intolerance, or where local protocols support dasatinib in earlier lines of therapy.

Each bottle of Spnib 100 mg supplied by Generic Meds Mart contains 30 film-coated dasatinib tablets. The 100 mg strength is commonly used in adult regimens, although the exact dose and schedule are always determined by a hematologist or oncologist based on disease phase, prior treatment, concomitant medicines and the patient’s overall health. Spnib 100 mg dasatinib tablets are taken by mouth, usually once daily, and are intended for long-term use as part of a continuous tyrosine kinase inhibitor strategy for Ph+ CML or Ph+ ALL where clinically appropriate.

Generic Meds Mart works only with licensed manufacturers and authorised distributors for oncology TKIs like Spnib 100 mg. Bottles are supplied in original, sealed packaging so that treating centres can verify brand, strength, batch number and expiry before dispensing. Outer shipping cartons are neutral, without visible references to leukemia or dasatinib, helping to protect patient privacy during international delivery. Prices are displayed in USD to make long-term therapy planning more transparent for patients and clinics.

Key Uses

Spnib 100 mg dasatinib tablets are used for guideline-based indications in Philadelphia chromosome–positive leukemias, according to local product information and specialist recommendations. In clinical practice, this typically includes:

Spnib 100 mg as a second-generation BCR-ABL inhibitor in adults with Ph+ CML, including chronic, accelerated or blast phase disease where dasatinib is considered appropriate by the treating team.

Spnib 100 mg in adults with Ph+ ALL when a potent oral TKI is required in induction, consolidation or maintenance phases alongside multi-agent chemotherapy or other targeted regimens, based on protocol.

Depending on region and label, dasatinib may be used either after imatinib failure or intolerance, or as a first-line option in selected patients. The decision to use Spnib 100 mg, and its position relative to other TKIs such as imatinib or nilotinib, must always be made by an experienced hematologist working within evidence-based guidelines.

How Dasatinib Works in Chemotherapy

Dasatinib, the active ingredient in Spnib 100 mg, is a potent inhibitor of the BCR-ABL tyrosine kinase, the abnormal fusion protein generated by the Philadelphia chromosome translocation t(9;22). This fusion kinase drives uncontrolled proliferation and survival of leukemic cells in Ph+ CML and Ph+ ALL.

By binding to and inhibiting BCR-ABL, dasatinib blocks downstream signalling pathways that support leukemic cell division and resistance to apoptosis. Dasatinib also inhibits other kinases, including members of the SRC family, which may contribute to its activity in leukemic cells. Compared with first-generation TKIs, dasatinib has broader binding characteristics and can retain activity against many imatinib-resistant BCR-ABL mutations, although some mutations remain problematic.

In clinical use, effective inhibition of BCR-ABL by Spnib 100 mg dasatinib tablets can lead to rapid reductions in leukocyte counts, improved bone marrow morphology and achievement of cytogenetic and molecular responses. Achieving and maintaining deep molecular responses is associated with better long-term outcomes in Ph+ CML and Ph+ ALL when managed according to specialist protocols.

Dosage & Administration

Spnib 100 mg must be prescribed and monitored by a hematologist or oncologist experienced in managing Ph+ leukemias. The usual adult dose and schedule are defined in the official product information and may vary according to indication, disease phase, prior therapies and local practice. Tablets are swallowed whole with water and should not be crushed or chewed.

Dasatinib can be taken with or without food, but patients should follow the exact instructions given by their treatment centre. Certain medicines, including proton pump inhibitors and strong CYP3A4 inhibitors or inducers, can affect dasatinib exposure and may need to be avoided or adjusted. Regular blood counts, liver function tests and clinical assessments are required to monitor response and toxicity. Dose interruptions, reductions or switches to an alternative TKI may be necessary in cases of significant myelosuppression, fluid retention, pulmonary events or other adverse effects. Patients should never change their Spnib 100 mg dose without specialist advice.

Precautions

Before starting Spnib 100 mg dasatinib tablets, the treatment team will review the patient’s medical history, ECG, cardiovascular status, liver and kidney function, concomitant medicines and bleeding risk. Dasatinib can cause myelosuppression, including neutropenia, thrombocytopenia and anemia, so frequent full blood count monitoring is essential, particularly in the first months of therapy.

Important precautions described in dasatinib prescribing information include risks of serious bleeding, fluid retention (such as pleural effusion and pericardial effusion), pulmonary arterial hypertension, QT interval prolongation and hepatotoxicity. Caution is required in patients with prior heart disease, uncontrolled hypertension, lung disease, liver impairment or those taking other QT-prolonging drugs. Women who are pregnant or may become pregnant should not handle dasatinib tablets without protection, and effective contraception is recommended for patients of reproductive potential.

Dasatinib Side Effects

Common side effects

Common dasatinib side effects in patients taking Spnib 100 mg include myelosuppression with low white cells, low platelets or anemia; headache; fatigue; nausea; vomiting; diarrhoea; abdominal discomfort; rash; musculoskeletal pain; mild fluid retention such as ankle swelling; and mild elevations in liver enzymes. Some patients experience cough or shortness of breath, which may be related to fluid around the lungs and must be assessed by the treating team.

These effects are often manageable with temporary treatment interruption, dose reduction, supportive therapy such as transfusions or growth factors and careful monitoring. Patients should attend all scheduled blood tests and clinic visits so that emerging issues can be detected early.

Serious side effects

Serious dasatinib adverse effects require urgent medical attention. These may include severe thrombocytopenia or neutropenia with increased risk of bleeding or infection; major haemorrhage; significant pleural or pericardial effusion; signs of pulmonary arterial hypertension such as progressive shortness of breath and fatigue; marked fluid overload; severe liver injury with jaundice; and serious cardiac events or marked QT prolongation.

Patients should contact emergency services or their treating centre immediately if they experience chest pain, severe shortness of breath, sudden swelling, black or bloody stools, coughing up blood, high fever, uncontrolled bleeding, confusion, severe dizziness or fainting. The treating team may need to interrupt Spnib 100 mg, adjust the dose or switch to an alternative therapy depending on the severity and type of adverse event.

Storage

Spnib 100 mg dasatinib tablets should be stored in the original, tightly closed bottle below 25 °C, protected from moisture and heat. The bottle should be kept out of the sight and reach of children and should not be stored in very humid environments such as bathrooms. Tablets must not be used after the expiry date shown on the label and carton. Unused or expired tablets should be returned to a pharmacy or disposed of in accordance with local oncology waste guidelines, not placed in household rubbish or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to specialist oral oncology medicines such as Spnib 100 mg dasatinib tablets. We source only from licensed manufacturers and authorised distributors who comply with Good Manufacturing Practice and maintain traceable batch records. Each bottle of Spnib 100 mg is supplied in sealed, original packaging so pharmacists and clinicians can verify brand name, strength, batch number and expiry before dispensing to patients.

Orders placed through Generic Meds Mart are billed in USD, simplifying cost planning for long-term TKI therapy. Shipments are packed in neutral outer cartons with no explicit mention of leukemia, dasatinib or Spnib 100 mg, and where available, tracking information is provided so that patients and clinics can coordinate refills before existing supplies run out. Our support team can help with ordering and logistics questions, while all decisions about whether to use a specific tyrosine kinase inhibitor remain exclusively with your hematology or oncology team.

Order Now

Spnib 100 mg dasatinib tablets are a potent, targeted therapy for Philadelphia chromosome–positive leukemias and must not be started without a detailed plan from an experienced specialist. Before you buy Spnib 100 mg online from Generic Meds Mart, ensure that your diagnosis, BCR-ABL status, prior TKI exposure and overall treatment goals have been fully discussed with your hematologist. You should have clear instructions about your daily dose, timing, monitoring schedule and what to do if doses are missed or side effects occur.

Once your plan is in place, your team can calculate how many bottles of Spnib 100 mg (1 bottle / 30 tabs) are needed for the initial treatment period. You can then select the appropriate quantity on Generic Meds Mart, add it to your cart and complete secure checkout in USD. Your medicine will be shipped in discreet packaging with full product labelling. You should never change, pause or stop dasatinib therapy on your own; any new or severe symptoms must be discussed promptly with your specialist team, and emergency services should be contacted when serious warning signs appear.

FAQ about Spnib (Dasatinib)

Q1: What is Spnib 100 mg used for?
Spnib 100 mg contains dasatinib, a second-generation BCR-ABL tyrosine kinase inhibitor used under specialist supervision for Philadelphia chromosome–positive chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL), according to local approvals and guidelines.

Q2: How should I take Spnib 100 mg tablets?
Spnib 100 mg dasatinib tablets are usually taken once daily, swallowed whole with water. You should follow the exact dose and timing given by your hematologist and avoid crushing or chewing the tablets. If you miss a dose, follow the instructions in your product leaflet or contact your clinic rather than doubling up the next day.

Q3: Will I need regular blood tests while on dasatinib?
Yes. Dasatinib can cause myelosuppression and other laboratory changes, so regular full blood counts and chemistry tests are essential, especially early in treatment. Your team will use these results to adjust your dose, pause therapy or provide supportive care if necessary.

Q4: Can Spnib 100 mg interact with other medicines?
Dasatinib is metabolised by CYP3A4 and can interact with many medicines, including certain antifungals, antibiotics, antivirals, anticonvulsants and stomach acid–reducing drugs. You should provide a full list of all prescription, over-the-counter and herbal products to your specialist, and never start or stop any medicine without checking for potential interactions.

Q5: How long will I need to stay on Spnib 100 mg?
Treatment duration with Spnib 100 mg dasatinib tablets is highly individual. Many patients remain on therapy for years to maintain deep molecular responses, while others may switch TKIs or change strategy if responses are suboptimal or side effects are problematic. Your hematologist will review your response milestones and overall health to decide whether to continue, adjust or change treatment over time.

Invista 100 mg Dasatinib Tablets (1 pack / 10 tabs)

At a Glance

Generic Name: Dasatinib

Brand Name: Invista

Strength & Pack Size: 100 mg per tablet; 1 pack / 10 tablets

Dosage Form & Route: Oral tablet, swallowed whole with water

Therapeutic Class: Tyrosine kinase inhibitor (BCR-ABL/Src family), targeted anticancer therapy

Primary Indication: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

Usual Adult Dose: Often 100 mg once daily in adult CML regimens, but dose and schedule are defined by your specialist

Prescription Status: Prescription-only medicine

Storage: Store below 25-30 °C in the original blister pack, protect from moisture and keep out of reach of children

Product Description

Invista 100 mg contains dasatinib, an oral targeted medicine used in certain blood cancers driven by abnormal tyrosine kinase signaling. It is prescribed for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in treatment settings where a specialist decides that dasatinib is appropriate. This pack provides 100 mg tablets supplied as 1 pack / 10 tablets, intended to support a planned treatment schedule and routine monitoring as directed by your hematology-oncology team.

Dasatinib is a prescription-only anticancer medicine and is not suitable for self-selection. In CML and Ph+ ALL care, your hematology-oncology team considers disease phase, prior therapies, comorbidities, infection history, bleeding risk, and potential drug interactions before choosing a regimen. Some patients receive dasatinib as first-line therapy, while others receive it after resistance or intolerance to another tyrosine kinase inhibitor, and the goals of treatment are always individualized.

Generic Meds Mart supplies Invista 100 mg dasatinib tablets in original manufacturer packaging sourced through licensed channels. The carton and blister typically show the brand name, strength, active ingredient, batch number, and expiry date so your clinic or pharmacy can verify product identity on receipt. Orders are processed with secure checkout in USD and shipped in discreet outer packaging to support privacy, with international delivery options designed to help patients coordinate refills with specialist monitoring. If you are comparing options, ask your clinic to confirm the correct strength and pack size before ordering and avoid making decisions based only on dasatinib price.

Key Uses

Invista 100 mg dasatinib is used to treat Philadelphia chromosome-positive chronic myeloid leukemia, including chronic phase and other phases when a specialist recommends a dasatinib-based approach. CML is a myeloproliferative cancer associated with the BCR-ABL fusion protein, and long-term disease control often depends on consistent kinase inhibition together with scheduled laboratory monitoring.

Dasatinib is also used in Philadelphia chromosome-positive acute lymphoblastic leukemia, usually as part of a specialist-led protocol that may include additional medicines. The exact indication, combination strategy, and duration are individualized, and your team will explain how response is assessed, how often blood tests are required, and which symptoms should prompt urgent contact.

How Dasatinib Works in Chemotherapy

Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL and members of the Src family, which are involved in signaling pathways that help malignant cells survive and proliferate. In Philadelphia chromosome-positive disease, BCR-ABL acts like a continuously active switch that drives abnormal cell growth. By blocking this signaling, dasatinib can reduce the growth advantage of leukemic cells and help bring blood counts and disease markers under control over time when therapy is taken consistently as prescribed.

Because dasatinib is a targeted inhibitor rather than a classic DNA-damaging chemotherapy, its effects and risks differ from many older regimens. Treatment still requires careful monitoring, and side effects can involve blood counts, fluid retention, bleeding tendency, or infections depending on individual risk factors and concomitant medicines. Your specialist balances expected benefit with safety and may adjust therapy based on laboratory trends, symptoms, and known interactions.

Dosage & Administration

Invista 100 mg tablets are taken by mouth exactly as prescribed by your hematology-oncology specialist. In adult CML regimens, dasatinib is often taken once daily, but the appropriate dose can differ depending on diagnosis, disease phase, response, tolerability, and other medicines. Swallow the tablet whole with water and take it at about the same time each day unless your clinic instructs otherwise.

Drug interactions can be clinically important with dasatinib. Certain strong CYP3A inhibitors or inducers may change drug exposure, and some acid-reducing medicines may need careful timing or alternatives because they can affect absorption. Always share a complete list of prescription medicines, over-the-counter products, and supplements with your specialist and pharmacist. If a dose is missed, follow your clinic’s instructions and do not take extra tablets to compensate unless your care team explicitly instructs you to do so.

Precautions

Dasatinib can cause myelosuppression, meaning reductions in white blood cells, red blood cells, and platelets. Regular blood tests are required, and dose interruptions or adjustments may be needed if cytopenias become significant. Contact your clinic urgently if you develop fever, chills, persistent sore throat, unusual bruising or bleeding, or severe fatigue, as these can signal infection, bleeding, or other complications that need prompt assessment.

Fluid retention is an important risk with dasatinib and may present as swelling, rapid weight gain, or pleural effusion with new or worsening cough or breathing difficulty. Some patients may experience pulmonary arterial hypertension, which requires specialist evaluation. Dasatinib may also increase bleeding risk, especially when combined with anticoagulants or antiplatelet medicines. Pregnancy should be avoided during treatment, and contraception planning should be discussed with your specialist before starting therapy.

Dasatinib Side Effects

Common side effects

Common dasatinib side effects may include headache, diarrhea, nausea, fatigue, muscle or joint aches, skin rash, and mild bruising. Blood tests may show anemia, neutropenia, or thrombocytopenia that require monitoring and, in some cases, supportive care or dose modification. Many effects are manageable when identified early, so report persistent or worsening symptoms rather than adjusting treatment on your own.

Serious side effects

Serious side effects require urgent medical attention and can include severe infection, heavy or unusual bleeding, marked shortness of breath, chest pain, or signs of significant fluid retention such as pleural effusion. Severe drops in blood counts, severe skin reactions, and clinically important liver test abnormalities can also occur. If you experience high fever, severe breathing difficulty, fainting, coughing up blood, or rapidly worsening symptoms, seek emergency care and inform clinicians that you are taking dasatinib.

Storage

Store Invista 100 mg below 25-30 °C, protected from moisture and direct heat, and keep the tablets in the original blister pack until use. Keep all medicines out of reach of children. Do not use the tablets after the expiry date printed on the carton or blister, and follow local guidance or your pharmacist’s advice for safe disposal of unused tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for specialty medicines such as Invista 100 mg dasatinib tablets. Products are supplied in original packaging from licensed channels with batch and expiry information to support verification by pharmacies and clinics, and discreet packaging helps protect privacy during delivery.

Prices are shown in USD to support planning, orders are processed with secure checkout, and worldwide delivery options can help patients coordinate refills with monitoring schedules and specialist visits. Generic Meds Mart does not replace your treating doctor; decisions about whether dasatinib is appropriate, how long to use it, and how to manage side effects must be made by qualified healthcare professionals.

Order Now

Before you buy Invista 100 mg online from Generic Meds Mart, you should have a confirmed diagnosis of Ph+ CML or Ph+ ALL and a treatment plan agreed with your hematology-oncology specialist. Your care team will advise which monitoring tests are needed and how often, and they will review interaction risks with your current medicines so your dasatinib dosage and schedule are clear.

Once your plan is confirmed, select Invista 100 mg (1 pack / 10 tabs), add it to your cart, and complete secure checkout in USD. Do not start therapy on your own, and do not stop or change dosing without medical guidance. If you develop concerning symptoms such as heavy bleeding, fever, signs of serious infection, chest pain, or persistent breathing problems, seek urgent medical care and inform clinicians that you are taking dasatinib.

FAQ about Invista (Dasatinib)

Q1: What is Invista 100 mg used for?

Invista 100 mg contains dasatinib, a tyrosine kinase inhibitor used in Philadelphia chromosome-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia when prescribed by a hematology-oncology specialist.

Q2: How should I take Invista 100 mg tablets?

Invista tablets are taken by mouth on a schedule defined by your specialist. Swallow the tablet whole with water and take it consistently as directed, with or without food depending on your clinic’s instructions.

Q3: Can Invista interact with other medicines?

Yes. Some medicines can change dasatinib exposure, and acid-reducing products may require careful timing or alternatives. Share a full list of medicines and supplements with your specialist so safe timing can be planned.

Q4: What should I do if I miss a dose?

If you miss a dose, follow your clinic’s instructions and do not take extra tablets to compensate unless your specialist tells you to. If you are unsure, contact your prescribing team for guidance.

Q5: What monitoring is usually needed during treatment?

Monitoring commonly includes blood counts and clinical checks for infection, bleeding symptoms, and breathing issues related to fluid retention, with frequency defined by your specialist based on your treatment plan.

Imatib Imatinib – 100 mg (1 pack / 10 tablets)

At a Glance

Brand name: Imatib

Generic name: Imatinib mesylate

Active ingredient: Imatinib

Strength & pack size: Imatib 100 mg (1 pack / 10 tablets)

Dosage form: Oral film-coated tablets

Main indication: Philadelphia chromosome–positive chronic myeloid leukemia (CML) and selected gastrointestinal stromal tumors (GIST)

Therapeutic class: Tyrosine kinase inhibitor (TKI)

Use in therapy: Targeted systemic treatment for Ph+ CML and indicated solid tumors

Prescription status: Prescription-only anticancer medicine

Supplied by: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from moisture and light

Product Description

Imatib 100 mg tablets are a generic imatinib mesylate medicine used in the treatment of specific blood cancers and solid tumors.
Imatinib is a well-known tyrosine kinase inhibitor (TKI) that has transformed outcomes for patients with
Philadelphia chromosome–positive chronic myeloid leukemia (CML) and certain gastrointestinal stromal tumors (GIST).
Imatib 100 mg (1 pack / 10 tablets) offers a compact pack size that may be used as an initial supply, a short bridging course or as continuation therapy,
always according to your specialist’s prescription.

Each Imatib tablet contains 100 mg of imatinib, taken by mouth, usually once or twice daily depending on the required total daily dose.
The 100 mg strength provides flexibility for dose titration and individualised treatment regimens. Because
Imatib is a generic imatinib product, it contains the same active ingredient as branded imatinib while offering a more accessible price in USD,
which can be important for patients who need long-term imatinib therapy.

When you buy Imatib 100 mg online from Generic Meds Mart, you receive imatinib tablets supplied by licensed manufacturers and authorised distributors
that follow recognised GMP standards. The medicine is shipped in plain, discreet outer packaging, while original blisters and cartons maintain full details such as strength, batch number and expiry date.

This Imatib 100 mg (1 pack / 10 tablets) product is intended only for patients already under the care of a haematologist or oncologist who has recommended
imatinib tablets as part of a treatment plan. Generic Meds Mart does not diagnose conditions or change treatment protocols;
the information on this page is designed to support informed discussions with your specialist about access to generic imatinib.

Key Uses

Imatib 100 mg imatinib tablets are typically used for the following indications under specialist supervision:

• Treatment of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic, accelerated or blast phase as directed
• Treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in selected patients
• Treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) expressing KIT (CD117) or other relevant targets
• Treatment of other rare malignancies where imatinib is specifically recommended in recognised oncology guidelines

Your specialist will determine how Imatib 100 mg fits into your therapy, what total daily dose you need and how long
imatinib treatment should continue.

How Imatinib Works in Chemotherapy

Imatinib is a targeted anticancer agent often grouped within modern systemic chemotherapy and targeted therapy regimens.
Imatib 100 mg contains imatinib, a tyrosine kinase inhibitor (TKI) that blocks abnormal signalling from specific tyrosine kinases such as BCR-ABL in CML
and KIT in many GIST tumours.

Imatib imatinib tablets work by binding to these overactive kinases and blocking their ATP-binding sites.
This disrupts the signalling pathways that drive uncontrolled cancer cell growth and survival. In
chronic myeloid leukemia, this targeted inhibition can reduce leukemic cell counts and support long-term disease control.
In GIST, inhibition of KIT may shrink or stabilise tumours that depend on this pathway.

Because imatinib acts as a targeted TKI rather than a traditional cytotoxic drug, its side effect profile differs from standard chemotherapy.
However, Imatib 100 mg is still a potent anticancer medicine that must be monitored carefully by an experienced haematologist or oncologist.

Dosage & Administration

Imatib 100 mg imatinib tablets must always be taken exactly as prescribed by your specialist.
Daily dosing, timing and duration of therapy depend on your diagnosis, disease phase, response and tolerance.

• Take Imatib tablets by mouth with a large glass of water; many patients are advised to take doses with food to reduce stomach discomfort.
• Swallow the tablets whole. Do not crush, split or chew Imatib 100 mg tablets unless your doctor or pharmacist has given specific instructions.
• The total daily dose may be taken once daily or divided into two doses, depending on your prescription and how well you tolerate treatment.
• Do not change your dose or stop taking Imatib without clear instructions from your haematologist or oncologist.
• If you miss a dose, follow your doctor’s advice; do not double the next dose to compensate unless your specialist has recommended it.

Your oncology team will schedule regular blood tests and other assessments to monitor your response to
Imatib imatinib therapy and to guide any necessary dose adjustments.

Precautions

Before starting Imatib 100 mg, inform your doctor about your full medical history and all medicines, supplements or herbal products you use. Important considerations include:

• History of liver disease, kidney impairment or significant cardiac disease
• Pre-existing fluid retention, swelling, heart failure or shortness of breath
• Previous or current gastrointestinal bleeding, ulcers or serious stomach or bowel conditions
• Use of other anticancer medicines, immunosuppressants or biologic therapies
• Use of strong CYP3A4 inhibitors or inducers, certain antibiotics, antifungals or antiepileptics that may interact with imatinib
• Use of paracetamol, anticoagulants or other medicines that may require careful monitoring with Imatib imatinib tablets

Imatinib may not be suitable during pregnancy, and effective contraception is usually recommended during treatment and for a period afterwards, as advised by your doctor.
Breastfeeding is often discouraged while taking Imatib. Your specialist will set an appropriate monitoring schedule in your case.

Imatinib Side Effects

Common side effects

Many patients experience side effects when starting Imatib imatinib tablets, especially during the first months of treatment. Common reactions may include:

• Nausea, mild vomiting or stomach discomfort
• Diarrhea or, in some cases, constipation
• Fluid retention with swelling of ankles, legs or around the eyes
• Muscle cramps, bone pain or joint discomfort
• Fatigue, weakness or general tiredness
• Mild skin rash or itching

These side effects are often manageable with supportive care or dose adjustments, but you should report persistent or troublesome symptoms to your oncology team.

Serious side effects

Some side effects of imatinib are less common but more serious and require urgent medical attention. Serious reactions may include:

• Marked fluid retention with sudden weight gain, worsening shortness of breath or pronounced leg swelling
• Signs of severe liver problems, such as yellowing of the skin or eyes, dark urine, pale stools or intense upper abdominal pain
• Severe abdominal pain, bloody stools or vomiting blood, which may indicate serious gastrointestinal issues
• Significant changes in blood counts, with fever, frequent infections, unusual bruising or prolonged bleeding
• Severe skin reactions, widespread rash, blistering or involvement of the mouth or eyes

If you experience any of these serious symptoms while taking Imatib 100 mg, seek immediate medical care and contact your specialist as soon as possible.

Storage

• Store Imatib 100 mg tablets at room temperature, usually below 25 °C, in a dry place away from direct sunlight and excess heat.
• Keep the tablets in their original blisters and carton until use to protect them from moisture and light.
• Keep Imatib imatinib tablets out of the sight and reach of children and pets.
• Do not use the medicine after the expiry date printed on the packaging.

Ask your pharmacist or follow local regulations for safe disposal of unused or expired imatinib tablets.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on providing reliable access to essential oncology medicines such as
Imatib 100 mg imatinib tablets at fair prices in USD.
We work only with licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a documented export track record.

When you buy Imatib 100 mg online from Generic Meds Mart, you benefit from:

• Competitive pricing on generic imatinib tablets compared with many local pharmacies
• Discreet, plain packaging designed to protect your privacy during shipping
• Tracked international delivery options to many destinations
• Clear, structured product information to support discussions with your haematologist or oncologist
• Customer support available to assist with ordering, payment and shipping questions

Our goal is to help you maintain continuity of prescribed targeted therapy with transparent conditions and professional handling of each order.

Order Now

Imatib 100 mg imatinib tablets are prescription-only anticancer medicines and must be used strictly under the supervision of a haematologist or oncologist.
Before you order Imatib 100 mg online, ensure that you have a valid prescription or written treatment plan specifying imatinib, the required daily dose and intended duration of therapy.

Select Imatib 100 mg (1 pack / 10 tablets), choose the appropriate quantity, add Imatib to your cart and complete the secure checkout process.
Your order will be processed, packed discreetly and shipped with tracking where available.

Generic Meds Mart does not provide diagnosis or personalised medical advice. All treatment decisions, dose changes and monitoring remain the responsibility of your oncology team.

Dasanat 50 mg Dasatinib Tablets (1 pack / 60 pills)

At a Glance

Generic Name: Dasatinib

Brand Name: Dasanat

Strength & Pack Size: 50 mg per tablet; 1 pack / 60 tablets

Dosage Form & Route: Oral tablet, swallowed whole with water

Therapeutic Class: Tyrosine kinase inhibitor (TKI), BCR-ABL inhibitor (targeted anticancer therapy)

Primary Indication: Chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) where dasatinib is appropriate

Typical Use in Therapy: Used within a hematology–oncology treatment plan with regular monitoring of blood counts and clinical status

Prescription Status: Prescription-only medicine

Storage: Store in original packaging as directed on the label; protect from moisture and keep out of reach of children

Product Description

Dasanat 50 mg contains dasatinib, an oral targeted anticancer medicine used in adults and selected patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) when a qualified hematology–oncology specialist determines it is appropriate. This presentation includes 50 mg dasatinib tablets in a 1 pack / 60 tablets format designed to support planned therapy continuity and specialist-led monitoring. If you need to buy Dasanat 50 mg online, confirm the exact strength and pack size with your treating team so your supply matches the prescribed plan.

CML and Ph+ ALL treatment is highly individualized. Your specialist considers disease phase, previous therapies, response milestones, bleeding risk, infection history, and potential drug interactions before selecting a BCR-ABL pathway inhibitor. Dasatinib is prescription-only and should not be started, stopped, or dose-adjusted without professional supervision. Decisions about switching between brands or sources should be made with your clinic to ensure safe continuity of therapy and consistent monitoring.

Generic Meds Mart supplies Dasanat 50 mg dasatinib tablets in original manufacturer packaging sourced through licensed channels. Packs typically display the product name, strength, active ingredient, batch number, and expiry date so your pharmacy or clinic can verify the medicine on receipt. Orders are shipped in discreet outer packaging to support privacy, and worldwide delivery options can help coordinate refills with scheduled blood tests and specialist visits.

Key Uses

Dasanat 50 mg (dasatinib) is used for CML and Ph+ ALL in situations where BCR-ABL tyrosine kinase inhibition is clinically appropriate. These are Philadelphia chromosome–driven blood cancers where targeted therapy can play a central role in disease control, and ongoing follow-up is essential to evaluate response and safety. Your hematology team defines treatment goals, monitoring intervals, and how to manage side effects or interactions during therapy.

Common Searches and Treatment Contexts for Dasatinib

• Generic Sprycel (Dasatinib): Dasanat is a therapeutically equivalent generic version of the brand-name drug Sprycel, containing the same active ingredient (dasatinib 50 mg) for the treatment of CML and Ph+ ALL.
• Dasatinib Tablets 50 mg: This strength may be prescribed as part of individualized dosing strategies determined by a hematology specialist based on response and tolerability.
• BCR-ABL TKI for CML: Dasatinib is a potent second-generation tyrosine kinase inhibitor that targets the BCR-ABL protein, a key driver in Philadelphia chromosome-positive leukemias.
• Buy Dasatinib Online: Patients with a confirmed prescription and monitoring plan may seek reliable access to original-packaging dasatinib to maintain therapy continuity.

How Dasatinib Works in Chemotherapy

Dasatinib works by inhibiting tyrosine kinases involved in leukemia cell signaling, including BCR-ABL, the abnormal fusion protein that drives Philadelphia chromosome–positive disease. In CML and Ph+ ALL, BCR-ABL signaling promotes uncontrolled growth and survival of malignant cells. By blocking these kinase signals, dasatinib can reduce downstream pathways that cancer cells rely on, supporting disease control when taken consistently as prescribed.

Because dasatinib is a targeted therapy rather than a classic cytotoxic chemotherapy, its safety profile differs from many traditional agents, but monitoring remains essential. Your specialist may monitor blood counts, fluid-related symptoms, bleeding risk, and infection signals, and may adjust the plan based on laboratory results and clinical assessment. Always follow specialist instructions and attend scheduled monitoring to ensure therapy remains safe and effective within your treatment plan.

Dosage & Administration

Dasanat 50 mg tablets must be taken exactly as prescribed by a hematology–oncology specialist. Dasatinib dosage is individualized and may be adjusted based on disease phase, treatment response, tolerability, and interacting medicines. Swallow the tablet whole with water and do not crush or chew it unless your specialist provides a specific instruction. If you miss a dose, follow your clinic’s guidance rather than taking extra tablets to compensate.

Drug interactions can be clinically important with dasatinib, and some medicines can affect exposure or increase bleeding risk. Always share a complete list of prescription medicines, over-the-counter products, and supplements with your specialist and pharmacist. Never self-adjust dosing, and do not stop therapy abruptly without medical advice, because continuity and monitoring are core parts of safe targeted treatment.

Precautions

Dasatinib can affect blood counts, which is why regular monitoring is a routine part of therapy even when you feel well. Low white blood cells can increase infection risk, low platelets can increase bleeding risk, and anemia can contribute to fatigue or shortness of breath. Report fever, chills, unusual bruising, prolonged bleeding, black stools, or new shortness of breath promptly so your care team can evaluate you.

Fluid-related effects may occur in some patients, including pleural effusion, which can cause cough, chest discomfort, or breathing difficulties. Your specialist will assess symptoms and may recommend investigations or plan adjustments if needed. Dasatinib can also interact with other medicines and supplements, so avoid starting new products without discussing them with your prescribing team. Pregnancy should be avoided during anticancer therapy, and contraception planning should be discussed with a qualified healthcare professional.

Dasatinib Side Effects

Common side effects

Common dasatinib side effects may include diarrhea, nausea, headache, fatigue, muscle or joint aches, skin rash, and laboratory changes in blood counts. Some patients experience mild bruising or swelling. Many effects can be managed within a specialist-led plan, but persistent or worsening symptoms should be discussed with your care team rather than managed by changing the dose independently.

Serious side effects

Serious side effects require urgent medical attention and may include significant reductions in blood counts with infection or bleeding, severe fluid accumulation around the lungs, major bleeding, severe shortness of breath, chest pain, fainting, or signs of severe infection. If you develop high fever, heavy bleeding, black stools, rapidly worsening breathing symptoms, or severe weakness, seek urgent care and tell clinicians you are taking dasatinib.

Storage

Store Dasanat 50 mg in the original packaging as directed on the label, with the container tightly closed if supplied in a bottle. Protect from moisture and excessive heat and keep out of reach of children. Do not use the medicine after the expiry date printed on the carton or container. If your clinic provides specific handling guidance for oncology medicines, follow it carefully.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for specialty medicines such as Dasanat 50 mg dasatinib tablets. Products are supplied in original packaging from licensed channels with batch and expiry information to support verification by pharmacies and clinics. Pricing is displayed in USD, checkout is secure, and orders are shipped in discreet outer cartons to protect privacy.

For patients managing CML or Ph+ ALL within a monitoring plan, reliable access can support therapy continuity. Worldwide delivery options and tracking can help align refills with blood tests and specialist visits. Generic Meds Mart does not replace your treating doctor, and all clinical decisions about dasatinib treatment, including monitoring and side effect management, must be made by qualified healthcare professionals.

Order Now

Before you order Dasanat 50 mg online, you should have a confirmed diagnosis of CML or Ph+ ALL and a treatment plan agreed with your hematology–oncology specialist. Your care team will explain the monitoring schedule and review interaction risks with your current medicines. Once your plan is confirmed, select Dasanat 50 mg (1 pack / 60 pills), add it to your cart, and complete secure checkout in USD with worldwide delivery options.

Do not start therapy on your own, and do not stop or change dosing without medical guidance. If you develop concerning symptoms such as heavy bleeding, high fever, chest pain, or worsening shortness of breath, seek urgent medical care and inform clinicians that you are taking dasatinib.

FAQ about Dasanat (Dasatinib)

Q1: What is Dasanat 50 mg used for?
Dasanat 50 mg contains dasatinib, a targeted tyrosine kinase inhibitor used in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) when prescribed by a hematology–oncology specialist.

Q2: Is Dasanat a chemotherapy medicine or targeted therapy?
Dasanat (dasatinib) is targeted therapy that inhibits BCR-ABL and related kinases involved in Philadelphia chromosome–positive disease. It is still an anticancer medicine and requires specialist supervision and monitoring.

Q3: How should I take Dasanat 50 mg tablets?
Take Dasanat exactly as prescribed. Swallow the tablet whole with water and follow your specialist’s instructions for timing, monitoring, and follow-up.

Q4: What should I know about dasatinib dosage and missed doses?
Dasatinib dosage is individualized by your specialist. If you miss a dose, follow your clinic’s instructions and do not take extra tablets unless your specialist tells you to.

Q5: What are common dasatinib side effects to monitor?
Common dasatinib side effects can include diarrhea, fatigue, rash, and changes in blood counts. Report persistent or severe symptoms so your care team can advise safely.

Q6: Is Dasanat 50 mg the same as Sprycel (Generic Sprycel)?
Dasanat 50 mg is Generic Sprycel — it contains the same active ingredient (dasatinib) as Sprycel. It’s used for the same indication at the same strength, while differences may be in manufacturer, inactive ingredients (excipients), tablet appearance, and packaging. If you’re switching between products, confirm the substitution with a qualified healthcare professional.

Cytosar Cytarabine – 100 mg Injection (1 pack / 5 ampoules)

At a Glance

Generic Name: Cytarabine

Brand Name: Cytosar

Strength & Pack Size: 100 mg per ampoule, 1 pack / 5 ampoules

Dosage Form & Route: Solution for IV, subcutaneous or intrathecal use in hospital settings

Therapeutic Class: Antimetabolite antineoplastic (pyrimidine analogue)

Primary Indications: Acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), blast crisis of chronic myeloid leukaemia and meningeal leukaemia

Typical Use in Therapy: Backbone component of induction, consolidation and maintenance chemotherapy regimens under specialist protocols

Mode of Action: S-phase–active DNA synthesis inhibitor via conversion to cytarabine triphosphate

Key Benefits: Long-established role in acute leukaemia protocols worldwide, including systemic and intrathecal schedules

Precautions: Profound myelosuppression, neurotoxicity, gastrointestinal toxicity and infection risk require close monitoring

Storage: Store in original packaging at the temperature specified in the leaflet; hospital pharmacy manages handling and disposal

Product Description

Cytosar 100 mg contains cytarabine, a pyrimidine analogue antimetabolite that has been a central part of acute leukaemia treatment for many years. This presentation provides five ampoules, each containing 100 mg cytarabine in solution for injection. Cytosar is intended exclusively for use in hospital or specialist clinic settings, where trained haematology–oncology teams prepare and administer it as part of structured chemotherapy protocols.

In clinical practice, cytarabine is used both as systemic therapy and, at appropriate doses and concentrations, as intrathecal prophylaxis or treatment for meningeal leukaemia. It is rarely, if ever, given as a stand-alone single agent; instead, Cytosar cytarabine is integrated into combination regimens with other cytotoxic drugs and supportive medicines designed to induce remission, consolidate response and reduce the risk of relapse. The 100 mg ampoule strength is convenient for flexible dosing calculations based on body surface area and protocol requirements.

Generic Meds Mart supplies Cytosar 100 mg cytarabine injection in original manufacturer cartons with clear cytotoxic labelling, batch numbers and expiry dates. We focus on structured access and logistics, working only with licensed distributors and manufacturers. All clinical decisions about whether cytarabine is appropriate, which doses to use, how to combine it with other medicines and how to manage side effects remain firmly with your treating haematology–oncology team.

Key Uses

Within locally approved indications and up-to-date guidelines, Cytosar 100 mg cytarabine injection is typically used for:

• Induction therapy in acute myeloid leukaemia (AML) when combined with anthracyclines or other agents.
• Consolidation and, in some protocols, maintenance or post-remission therapy for AML.
• Selected regimens in acute lymphoblastic leukaemia (ALL) and in blast crisis of chronic myeloid leukaemia (CML) where cytarabine-containing combinations are appropriate.
• Intrathecal treatment or prophylaxis of meningeal leukaemia as part of central nervous system–directed therapy.

The exact indication, schedule and use of Cytosar are defined by specialist treatment protocols that take into account age, comorbidities, previous therapy, cytogenetic and molecular risk, and local standards of care.

How Cytarabine Works in Chemotherapy

Cytarabine, the active ingredient in Cytosar 100 mg injection, is a cytosine arabinoside–based antimetabolite that interferes with DNA synthesis. After administration, cytarabine is taken up by cells and converted intracellularly to its active metabolite, cytarabine triphosphate (Ara-CTP). Ara-CTP competes with the natural nucleoside deoxycytidine triphosphate for incorporation into DNA, leading to faulty DNA chains and inhibition of DNA polymerase.

Because these actions are most pronounced in the S-phase of the cell cycle, cytarabine preferentially affects rapidly dividing cells, including leukaemic blasts. By inhibiting DNA replication and repair mechanisms in these malignant cells, Cytosar can contribute to their death during intensive chemotherapy regimens. This S-phase specificity and the ability to achieve high concentrations in the central nervous system with certain dosing schedules underpin cytarabine’s role in both systemic and intrathecal leukaemia therapy.

Dosage & Administration

All dosing and administration of Cytosar 100 mg cytarabine injection must be determined by experienced haematologists or oncologists following established protocols and product information. Cytarabine regimens vary widely and may include low-dose, intermediate-dose or high-dose schedules, delivered as intermittent IV boluses, short infusions, continuous infusions or subcutaneous injections. In selected cases and at appropriate concentrations, cytarabine is administered intrathecally as part of CNS-directed leukaemia therapy.

Dose and schedule are typically based on body surface area, disease type, treatment phase, organ function and prior therapies. Intensive cytarabine therapy requires hospital admission, specialist nursing care and access to transfusion support, infection management and close laboratory monitoring. Cytosar must never be self-administered and should not be handled by patients or caregivers at home outside of a clear and approved hospital-directed plan.

Precautions

Cytarabine is associated with profound bone marrow suppression, which can lead to severe neutropenia, thrombocytopenia and anaemia. As a result, patients receiving Cytosar 100 mg injection require frequent full blood counts and, where necessary, red cell and platelet transfusions, growth factor support and infection prophylaxis or treatment. Fever, mucositis, unexplained bruising or bleeding and signs of infection require urgent clinical assessment.

At higher doses, cytarabine can cause specific neurotoxicities, including cerebellar dysfunction with ataxia, dysarthria and nystagmus, particularly in older patients or those with renal impairment. Eye toxicity such as conjunctivitis and keratitis may occur, and prophylactic steroid eye drops are often recommended during high-dose cytarabine therapy according to local protocols. Cytarabine can also contribute to gastrointestinal toxicity (nausea, vomiting, diarrhoea, abdominal pain), hepatic enzyme elevations and, rarely, pulmonary toxicity or myocardial impairment.

Cytarabine is teratogenic and should be avoided in pregnancy unless potential benefit clearly outweighs risk and no safer alternatives exist. Effective contraception is recommended for patients and partners during and after treatment as advised by the specialist team. Breastfeeding is usually not recommended during cytarabine therapy. All concomitant medicines, including other chemotherapy, antibiotics, antifungals and antivirals, should be reviewed for interactions and overlapping toxicities.

Cytarabine Side Effects

Common side effects

Common cytarabine side effects with Cytosar 100 mg injection, particularly at standard doses, include bone marrow suppression with low white blood cells, red cells and platelets, fatigue, fever, mucositis, nausea, vomiting, decreased appetite, mild liver enzyme elevations, hair thinning or loss, injection-site irritation and transient rash. Many patients also experience general malaise and increased susceptibility to infections during nadir periods.

These common cytarabine side effects are typically managed with planned supportive care: antiemetics, mouth care protocols, transfusions, growth factors where appropriate, infection surveillance and prompt antibiotic therapy. Regular monitoring allows clinicians to distinguish manageable toxicity from early warning signs of more serious complications that may require dose adjustment or treatment interruption.

Serious side effects

Serious cytarabine adverse effects require urgent specialist attention. These can include severe or prolonged bone marrow suppression with sepsis or life-threatening infections, significant bleeding, high-grade mucositis, severe diarrhoea, signs of cerebellar toxicity (unsteady gait, slurred speech, difficulty with coordination), seizures, confusion, severe visual disturbance, acute respiratory distress, chest pain or signs of myocardial injury.

If any of these warning signs occur during a Cytosar-containing regimen, patients should seek immediate medical care and inform their treating team that they are receiving cytarabine. The haematology–oncology team may need to stop or modify treatment, arrange urgent investigations, escalate supportive therapy and manage complications in a high-dependency or intensive care setting where necessary.

Storage

Cytosar 100 mg cytarabine injection should be stored in its original carton at the temperature recommended in the product leaflet, protected from light and extremes of heat. In practice, storage and handling are usually managed entirely by hospital or specialist clinic pharmacies, which also ensure correct preparation, dilution and disposal in line with cytotoxic safety regulations. Ampoules should not be used after the expiry date on the pack, and any unused solution or materials in contact with cytarabine must be discarded according to local hazardous waste procedures.

Why Buy from Generic Meds Mart

Generic Meds Mart is dedicated to structured access for essential oncology and haematology medicines such as Cytosar 100 mg cytarabine injection. We work only with licensed manufacturers and authorised distributors, and we supply Cytosar in original cartons with clearly visible batch numbers and expiry dates so that hospital and clinic pharmacies can verify authenticity and traceability.

Pricing is shown in USD to assist hospitals, clinics and patients in budgeting for multi-cycle acute leukaemia treatment plans. We ship using neutral outer packaging with no reference to cancer, chemotherapy or leukaemia on the outside, and we offer trackable shipping options where regulations allow. Our role is limited to supply and logistics; we do not make medical decisions and do not advise on individual cytarabine dosing, regimen selection or suitability.

Order Now

Cytosar 100 mg cytarabine injection is a potent antineoplastic medicine that must only be used within carefully controlled hospital protocols. Before arranging supply through Generic Meds Mart, ensure that a haematology–oncology team has confirmed the diagnosis, defined a cytarabine-containing regimen, reviewed organ function and discussed risks and benefits in detail with the patient or caregivers.

Once a clear plan is in place, the treating centre or authorised purchaser can calculate how many packs of Cytosar 100 mg (1 pack / 5 amps) are needed for induction, consolidation or CNS-directed phases. The required quantities can then be ordered on Generic Meds Mart, added to the cart and checked out securely in USD. Medicines will be shipped in discreet packaging, but all aspects of administration, monitoring, side-effect management and decisions about dose changes or discontinuation must remain with the specialist team, not the patient.

FAQ about Cytosar (Cytarabine)

Q1: What is Cytosar used for?
Cytosar contains cytarabine, an antimetabolite chemotherapy medicine primarily used in combination regimens for acute myeloid leukaemia (AML), certain acute lymphoblastic leukaemia (ALL) protocols, blast crisis of chronic myeloid leukaemia and intrathecal treatment or prophylaxis of meningeal leukaemia, according to local guidelines.

Q2: Is Cytosar given as an injection or infusion?
Cytosar 100 mg cytarabine injection is supplied as a solution in ampoules that can be given as IV bolus, short infusion, continuous infusion, subcutaneous injection or intrathecal dose, depending on the protocol. The exact method is determined by the treating haematology–oncology team and is always carried out in a controlled medical setting.

Q3: Why does Cytosar require so much monitoring?
Cytarabine can cause profound bone marrow suppression, serious infections and organ toxicities, especially at higher doses. Frequent blood tests, neurological checks, eye assessments, infection surveillance and supportive care measures are needed to keep treatment as safe and effective as possible. Monitoring requirements are part of the reason Cytosar is reserved for specialised centres.

Q4: Can Cytosar be taken at home?
Cytosar 100 mg cytarabine injection is not a self-administered medicine and is not intended for routine home use by patients or caregivers. Even when parts of a regimen are delivered in an outpatient setting, preparation and administration are handled by trained professionals with access to emergency support. Any questions about where treatment will take place should be discussed with the treating team.

Q5: Does Cytosar cure leukaemia?
Cytarabine is a key component of many curative-intent protocols for acute leukaemia, but it is rarely the only drug used, and long-term outcomes depend on multiple factors, including leukaemia subtype, risk profile, response to therapy and any subsequent transplantation or maintenance strategies. Only your haematology–oncology team can explain the realistic goals of a Cytosar-containing regimen in your specific situation.

6-MP 50 mg Mercaptopurine Tablets (1 pack / 100 tabs)

At a Glance

Generic Name: Mercaptopurine

Brand Name: 6-MP

Strength & Pack Size: 50 mg per tablet; 1 pack / 100 tablets

Dosage Form & Route: Oral tablet, taken by mouth with water as prescribed

Therapeutic Class: Antimetabolite (thiopurine), cytotoxic anticancer medicine

Primary Indication: Acute lymphoblastic leukemia (ALL) maintenance therapy as part of a specialist-directed regimen

Usual Adult Dose: Individualised dosing based on protocol, body size and blood counts; follow your oncology team’s plan

Prescription Status: Prescription-only medicine

Storage: Store at room temperature in the original packaging, protected from moisture and light

Product Description

6-MP 50 mg contains mercaptopurine, a thiopurine antimetabolite used as part of maintenance therapy for acute lymphoblastic leukemia (ALL) and other protocol-defined settings in hematology–oncology care. This product is supplied as 50 mg tablets in a 1 pack / 100 tabs presentation to support planned treatment cycles and ongoing monitoring. Mercaptopurine is a prescription-only cytotoxic medicine and must only be used within a confirmed diagnosis and a regimen designed by a qualified specialist.

In ALL care, maintenance therapy is structured and long-term, and it depends on careful dose adjustment rather than a one-size-fits-all approach. Your treating team considers age, body size, liver function, infection risk, prior therapy, and laboratory trends when selecting a mercaptopurine dose. The goal is to maintain effective therapy while keeping side effects manageable through planned monitoring. Because mercaptopurine can significantly affect blood counts and liver tests, scheduled follow-up is an essential part of treatment, even when you feel well.

Generic Meds Mart supplies 6-MP 50 mg mercaptopurine tablets in original packaging sourced through licensed channels. Packs typically show the brand name, strength, active ingredient, batch number, and expiry date so your pharmacy or clinic can verify the product on receipt. Orders are processed with secure checkout in USD and shipped in discreet outer packaging to support privacy. If you are comparing options, ask your clinic to confirm the correct strength and pack size before ordering, and avoid making decisions based only on mercaptopurine price.

Key Uses 6-MP (Mercaptopurine) for Acute Lymphoblastic Leukemia (ALL) Maintenance Therapy

6-MP 50 mg mercaptopurine is primarily used in acute lymphoblastic leukemia maintenance therapy under specialist supervision. Maintenance therapy is commonly used after induction and consolidation phases to help sustain remission, and it is usually combined with other medicines according to the protocol selected by your hematology–oncology team. The exact combination, schedule, and duration depend on the specific treatment plan and regional guidelines.

Mercaptopurine may also be used in other carefully defined hematology settings where thiopurines are part of an established protocol. The indication and dosing are always defined by the treating specialist, because the balance between benefit and risk depends on blood count monitoring, liver function monitoring, and assessment of infection risk. If you need to order mercaptopurine tablets online, ensure you have written instructions from your clinic covering dosing, missed-dose rules, and the frequency of required lab tests.

How Mercaptopurine Works in Chemotherapy

Mercaptopurine is an antimetabolite that interferes with the synthesis of nucleic acids, which are essential for cell replication and growth. After it is taken by mouth, mercaptopurine is converted into active metabolites that can disrupt the production and function of DNA and RNA. Leukemia cells, which divide and renew rapidly, may be particularly affected when these pathways are inhibited, helping maintenance therapy support long-term disease control in protocol-based care.

Because mercaptopurine targets fundamental cellular processes, it can also affect some normal rapidly dividing cells, especially in the bone marrow. This is why blood counts must be monitored and why dosing is often adjusted over time. The same mechanism that supports therapeutic effect can also contribute to side effects such as neutropenia or anemia, and your specialist uses regular lab monitoring to keep treatment within safe limits while maintaining the intended regimen.

Dosage & Administration

6-MP 50 mg tablets are taken by mouth exactly as prescribed by a hematology–oncology specialist. Dosing is typically individualized and adjusted based on treatment protocol, body size, blood counts, liver function tests, and clinical tolerance. Your clinic may provide specific instructions about the time of day to take mercaptopurine and whether to take it with food, and it is important to follow the same routine consistently unless your specialist advises a change.

Swallow the tablet with water and do not change the dose on your own. Never take extra tablets to “catch up” after a missed dose unless your clinic explicitly instructs you to do so. Drug interactions can be clinically important, and certain medicines can increase the risk of side effects, so always share a complete list of prescriptions, over-the-counter products, and supplements with your healthcare team. If you are unsure how to take a dose on a day you feel unwell, contact your treating team rather than adjusting the medicine yourself.

Precautions

Mercaptopurine can cause significant bone marrow suppression, leading to low white blood cells, low platelets, and anemia. This increases the risk of infection and bleeding, and it is why regular blood tests are required during therapy. Fever, chills, persistent sore throat, mouth ulcers, unusual bruising, bleeding, or shortness of breath should be reported urgently to your clinic so you can be assessed promptly.

Liver-related side effects are also possible, and your specialist will typically monitor liver enzymes and other laboratory markers. You should tell your team if you develop yellowing of the skin or eyes, dark urine, severe nausea, persistent vomiting, or right-sided abdominal pain. Because immune suppression may increase the risk of infections, your clinic may advise practical precautions and may review vaccines and exposure risks based on your situation.

Mercaptopurine may harm an unborn baby, so pregnancy should be avoided during treatment and contraception planning should be discussed with your specialist. Do not start new medicines without checking with your treating team, especially medicines that may affect the immune system or liver function. Your clinic will define the monitoring plan and may adjust treatment based on blood counts, liver tests, and your overall response.

Mercaptopurine Side Effects

Common side effects

Common mercaptopurine side effects may include nausea, decreased appetite, mild stomach discomfort, tiredness, and changes in blood tests such as lowered blood counts or mild liver enzyme elevations. Some people notice increased susceptibility to infections because of reduced white blood cells, and minor mouth soreness can occur. These effects are often managed by monitoring, supportive care, and dose adjustments within the specialist-led plan, and you should report ongoing symptoms rather than altering the dose independently.

Serious side effects

Serious side effects require urgent medical attention and may include severe neutropenia with fever, serious infections, significant bleeding or bruising from low platelets, severe anemia with marked weakness or shortness of breath, and signs of significant liver injury such as jaundice or dark urine. Severe abdominal pain, persistent vomiting, or rapidly worsening weakness should be assessed promptly. If you develop high fever, confusion, chest pain, uncontrolled bleeding, or severe shortness of breath, seek urgent care and tell clinicians you are receiving mercaptopurine.

Storage

Store 6-MP 50 mg mercaptopurine tablets at room temperature in the original packaging, protected from moisture and direct light. Keep the pack tightly closed if supplied in a bottle, and keep all medicines out of reach of children and pets. Do not use the tablets after the expiry date printed on the packaging. If your clinic provides specific handling guidance for cytotoxic medicines in the home, follow it carefully, and ask your pharmacist about safe disposal of unused tablets.

Why Choose Generic Meds Mart for Your 6-MP (Mercaptopurine) Supply?

We bridge the gap between your doctor’s prescription and reliable access to essential medication.

Our Role: We are a reliable supplier, not a substitute for your medical team.

Mercaptopurine requires specialist monitoring and careful dose adjustment, and Generic Meds Mart does not replace your treating doctor. Decisions about whether mercaptopurine is appropriate, how it fits into your protocol, and how to manage side effects must be made by qualified healthcare professionals. Our role is to help you obtain the medicine your clinic has prescribed and to support predictable access for ongoing therapy.

Order Now

Before you buy 6-MP 50 mg online from Generic Meds Mart, you should have a confirmed diagnosis and a mercaptopurine-based plan agreed with your hematology–oncology team. Your clinic will advise how often you need blood counts and liver function tests, how missed doses should be handled, and what symptoms require urgent contact. Once your plan is confirmed, select 6-MP 50 mg (1 pack / 100 tabs), add it to your cart, and complete secure checkout in USD.

Do not start mercaptopurine on your own and do not change dosing without medical guidance. If you develop fever, signs of infection, unusual bleeding, severe weakness, or symptoms that suggest liver problems, contact your clinic urgently or seek emergency care and inform clinicians that you are taking mercaptopurine.

FAQ about 6-MP (Mercaptopurine)

Q1: What is 6-MP 50 mg used for?

6-MP 50 mg contains mercaptopurine, an antimetabolite medicine used mainly as part of specialist-directed maintenance therapy for acute lymphoblastic leukemia (ALL) according to a defined treatment protocol.

Q2: How do I take mercaptopurine tablets?

Mercaptopurine tablets are taken by mouth on a schedule prescribed by your hematology–oncology team. Swallow the tablet with water and follow your clinic’s instructions about timing and consistency, and never self-adjust the dose.

Q3: Why are regular blood tests needed during treatment?

Mercaptopurine can lower blood counts and affect liver tests, so regular monitoring helps your specialist adjust dosing safely and detect problems early. This monitoring is a key part of maintenance therapy planning.

Q4: What should I do if I miss a dose?

Follow your clinic’s written instructions for missed doses and do not take extra tablets unless your treating team specifically tells you to. If you are unsure, contact your prescribing team for guidance.

Q5: What symptoms should be treated as urgent during mercaptopurine therapy?

Fever, chills, sore throat, unusual bruising or bleeding, severe weakness, shortness of breath, or signs of liver problems such as jaundice should be reported urgently. If symptoms are severe or rapidly worsening, seek emergency care and tell clinicians you are taking mercaptopurine.